(Q39455947)

12 September 2017

title

Multivalent rituximab lipid nanoparticles as improved lymphoma therapies: indirect mechanisms of action and in vivo activity (English)

1 reference

12 September 2017

0 references

1 reference

Jesse Popov

1

1 reference

12 September 2017

Anita I Kapanen

2

1 reference

12 September 2017

Christopher Turner

3

1 reference

12 September 2017

Rebecca Ng

4

1 reference

12 September 2017

Catherine Tucker

5

1 reference

12 September 2017

Gigi Chiu

6

1 reference

12 September 2017

Richard Klasa

7

1 reference

12 September 2017

Marcel B Bally

8

1 reference

12 September 2017

Ghania Chikh

9

1 reference

12 September 2017

language of work or name

1 reference

20 October 2011

1 reference

12 September 2017

1 reference

12 September 2017

volume

6

1 reference

12 September 2017

issue

9

1 reference

12 September 2017

page(s)

1575-1591

1 reference

Therapeutic antibodies: past, present and future.

12 September 2017

cites work

1 reference

Strategies and challenges for the next generation of therapeutic antibodies

21 January 2018

1 reference

Monoclonal antibodies: versatile platforms for cancer immunotherapy

21 January 2018

1 reference

CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma

21 January 2018

1 reference

Anti-CD20 monoclonal antibodies: historical and future perspectives

21 January 2018

1 reference

CD20 homo-oligomers physically associate with the B cell antigen receptor. Dissociation upon receptor engagement and recruitment of phosphoproteins and calmodulin-binding proteins

21 January 2018

1 reference

CD20-mediated apoptosis: signalling through lipid rafts

21 January 2018

1 reference

Cancer resistance to complement-dependent cytotoxicity (CDC): Problem-oriented research and development

21 January 2018

1 reference

Complement activation determines the therapeutic activity of rituximab in vivo.

21 January 2018

1 reference

Rituximab infusion promotes rapid complement depletion and acute CD20 loss in chronic lymphocytic leukemia

21 January 2018

1 reference

Mapping of binding epitopes of a human decay-accelerating factor monoclonal antibody capable of enhancing rituximab-mediated complement-dependent cytotoxicity

21 January 2018

1 reference

Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets

21 January 2018

1 reference

Expression of the ULBP ligands for NKG2D by B-NHL cells plays an important role in determining their susceptibility to rituximab-induced ADCC.

21 January 2018

1 reference

A new mechanism of NK cell cytotoxicity activation: the CD40-CD40 ligand interaction.

21 January 2018

1 reference

Cellular and molecular signal transduction pathways modulated by rituximab (rituxan, anti-CD20 mAb) in non-Hodgkin's lymphoma: implications in chemosensitization and therapeutic intervention

21 January 2018

1 reference

Molecular mechanisms of resistance to Rituximab and pharmacologic strategies for its circumvention

21 January 2018

1 reference

From the bench to the bedside: ways to improve rituximab efficacy.

21 January 2018

1 reference

Fas receptor clustering and involvement of the death receptor pathway in rituximab-mediated apoptosis with concomitant sensitization of lymphoma B cells to fas-induced apoptosis

21 January 2018

1 reference

Rituxan (anti-CD20 antibody)-induced translocation of CD20 into lipid rafts is crucial for calcium influx and apoptosis.

21 January 2018

1 reference

Generation of rituximab polymer may cause hyper-cross-linking-induced apoptosis in non-Hodgkin's lymphomas

21 January 2018

1 reference

Homodimers but not monomers of Rituxan (chimeric anti-CD20) induce apoptosis in human B-lymphoma cells and synergize with a chemotherapeutic agent and an immunotoxin.

21 January 2018

1 reference

Design, Construction, and In Vitro Analyses of Multivalent Antibodies

21 January 2018

1 reference

Synthesis and evaluation of multivalent branched HPMA copolymer-Fab' conjugates targeted to the B-cell antigen CD20.

21 January 2018

1 reference

Novel designs of multivalent anti-CD20 humanized antibodies as improved lymphoma therapeutics

21 January 2018

1 reference

Association with membrane protrusions makes ErbB2 an internalization-resistant receptor

21 January 2018

1 reference

Signal transduction of erbB receptors in trastuzumab (Herceptin) sensitive and resistant cell lines: local stimulation using magnetic microspheres as assessed by quantitative digital microscopy.

21 January 2018

1 reference

Four human t(11;14)(q13;q32)-containing cell lines having classic and variant features of Mantle Cell Lymphoma.

21 January 2018

1 reference

Vesicles of variable sizes produced by a rapid extrusion procedure

21 January 2018

1 reference

Targeting of antibody conjugated, phosphatidylserine-containing liposomes to vascular cell adhesion molecule 1 for controlled thrombogenesis.

21 January 2018

1 reference

A simplified method for the rapid fluorometric assessment of antibody-dependent cell-mediated cytotoxicity.

21 January 2018

1 reference

Z-138: a new mature B-cell acute lymphoblastic leukemia cell line from a patient with transformed chronic lymphocytic leukemia

21 January 2018

1 reference

Multivalent antibodies: when design surpasses evolution.

21 January 2018

1 reference

CD16 polymorphisms and NK activation induced by monoclonal antibody-coated target cells.

21 January 2018

1 reference

Natural killer (NK) cell response to virus infections in mice with severe combined immunodeficiency. The stimulation of NK cells and the NK cell-dependent control of virus infections occur independently of T and B cell function

21 January 2018

1 reference

Tumor burden influences exposure and response to rituximab: pharmacokinetic-pharmacodynamic modeling using a syngeneic bioluminescent murine model expressing human CD20.

21 January 2018

1 reference

Surface-active liposomes for targeted cancer therapy

21 January 2018

1 reference

Epstein-Barr virus: 40 years on

21 January 2018

1 reference

Rituximab and CHOP induction therapy for newly diagnosed mantle-cell lymphoma: molecular complete responses are not predictive of progression-free survival

21 January 2018

1 reference

Monoclonal Antibody Therapy for B-Cell Non-Hodgkin's Lymphoma

21 January 2018

1 reference

Complement component C1q enhances the biological activity of influenza virus hemagglutinin-specific antibodies depending on their fine antigen specificity and heavy-chain isotype

21 January 2018

1 reference

Activation of the first component of complement

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.2217/NNM.11.50

1 reference

release_dvedp4elhnbjxbuhmgrvhakpo4

12 September 2017

Fatcat ID

0 references

1 reference